II期临床试验-话题@MedSci

#II期临床试验#

174篇内容 | 3281人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1931486, encodeId=71051931486c6, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=复杂腹腔内感染的治疗：口服和静脉注射Sulopenem的III期临床试验结果, objectType=article, longId=184569, objectId=5a93184569d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a93184569d3, replyNumber=0, likeNumber=54, createdTime=2020-08-07, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a93184569d3, moduleTitle=复杂腹腔内感染的治疗：口服和静脉注射Sulopenem的III期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a93184569d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931455, encodeId=542619314551c, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=赛诺菲：Dupixent（dupilumab）治疗严重慢性鼻窦炎、鼻息肉的两项III期临床试验取得了积极成果 , objectType=article, longId=161247, objectId=7cfc16124ea4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cfc16124ea4, replyNumber=0, likeNumber=73, createdTime=2019-09-11, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cfc16124ea4, moduleTitle=赛诺菲：Dupixent（dupilumab）治疗严重慢性鼻窦炎、鼻息肉的两项III期临床试验取得了积极成果 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cfc16124ea4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931487, encodeId=158e193148e84, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=葛兰素史克宣布贝利尤单抗治疗狼疮性肾炎患者的III期临床试验取得整体阳性结果, objectType=article, longId=184997, objectId=556218499e7a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=556218499e7a, replyNumber=0, likeNumber=60, createdTime=2020-08-26, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=556218499e7a, moduleTitle=葛兰素史克宣布贝利尤单抗治疗狼疮性肾炎患者的III期临床试验取得整体阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=556218499e7a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931463, encodeId=280c193146340, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=阿斯利康靶向HER2的抗体药物偶联物在II期临床试验中显示出治疗前景, objectType=article, longId=165882, objectId=9c0116588208, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c0116588208, replyNumber=0, likeNumber=58, createdTime=2019-08-16, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c0116588208, moduleTitle=阿斯利康靶向HER2的抗体药物偶联物在II期临床试验中显示出治疗前景, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c0116588208)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931449, encodeId=a215193144920, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=以胸腺素β4为活性成分的新型治疗肽正进行干眼症的III期临床试验, objectType=article, longId=160421, objectId=524e160421b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=524e160421b4, replyNumber=0, likeNumber=54, createdTime=2019-05-20, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=524e160421b4, moduleTitle=以胸腺素β4为活性成分的新型治疗肽正进行干眼症的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=524e160421b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931467, encodeId=50f3193146ea0, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=国产艾滋病疫苗II期临床试验启动：1500元补助招志愿者, objectType=article, longId=168391, objectId=bfb4168391a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfb4168391a4, replyNumber=0, likeNumber=64, createdTime=2020-03-14, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfb4168391a4, moduleTitle=国产艾滋病疫苗II期临床试验启动：1500元补助招志愿者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfb4168391a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931477, encodeId=286619314e770, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=阿斯利康的EGFR抑制剂Tagrisso在III期临床试验中显著改善NSCLC的总体存活率, objectType=article, longId=177383, objectId=b6d81e73834c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6d81e73834c, replyNumber=0, likeNumber=72, createdTime=2020-06-19, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6d81e73834c, moduleTitle=阿斯利康的EGFR抑制剂Tagrisso在III期临床试验中显著改善NSCLC的总体存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6d81e73834c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931469, encodeId=080119314699f, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=赛诺菲/Regeneron的IL-13单抗REGN3500治疗哮喘II期临床试验成功, objectType=article, longId=172193, objectId=f8e41e2193df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8e41e2193df, replyNumber=0, likeNumber=56, createdTime=2020-06-04, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8e41e2193df, moduleTitle=赛诺菲/Regeneron的IL-13单抗REGN3500治疗哮喘II期临床试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8e41e2193df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931474, encodeId=39e519314e47b, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=Sanfilippo综合征A型的基因疗法：基因疗法ABO-102的I/II期临床试验取得阶段性成果, objectType=article, longId=176224, objectId=18291e622416, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18291e622416, replyNumber=0, likeNumber=68, createdTime=2019-11-17, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18291e622416, moduleTitle=Sanfilippo综合征A型的基因疗法：基因疗法ABO-102的I/II期临床试验取得阶段性成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18291e622416)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931482, encodeId=b8541931482f1, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=Cymerus MSCs治疗骨关节炎的II期临床试验取得新进展, objectType=article, longId=180575, objectId=9db31805e5fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9db31805e5fb, replyNumber=0, likeNumber=100, createdTime=2020-06-12, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9db31805e5fb, moduleTitle=Cymerus MSCs治疗骨关节炎的II期临床试验取得新进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9db31805e5fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931457, encodeId=732d193145e5d, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=2019年美国皮肤病学会（AAD）年会：Bermekimab治疗特应性皮炎的II期临床试验取得突破性成果, objectType=article, longId=161551, objectId=9ed316155121, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ed316155121, replyNumber=0, likeNumber=68, createdTime=2020-01-24, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ed316155121, moduleTitle=2019年美国皮肤病学会（AAD）年会：Bermekimab治疗特应性皮炎的II期临床试验取得突破性成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ed316155121)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931472, encodeId=f95619314e2a1, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=III期临床试验显示：诺华的CGRP抑制剂Aimovig治疗偏头痛展现出长期疗效, objectType=article, longId=174669, objectId=3b101e46693f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b101e46693f, replyNumber=0, likeNumber=80, createdTime=2020-01-31, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b101e46693f, moduleTitle=III期临床试验显示：诺华的CGRP抑制剂Aimovig治疗偏头痛展现出长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b101e46693f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931466, encodeId=d96c193146641, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=辉瑞公布LYRICA（普瑞巴林）治疗原发性全身强直-阵挛性癫痫发作的III期临床试验结果, objectType=article, longId=166801, objectId=1b1b16680115, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b1b16680115, replyNumber=0, likeNumber=69, createdTime=2020-03-04, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b1b16680115, moduleTitle=辉瑞公布LYRICA（普瑞巴林）治疗原发性全身强直-阵挛性癫痫发作的III期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b1b16680115)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931481, encodeId=5f7b1931481aa, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=Onngsertib治疗转移性去势抵抗性前列腺癌的II期临床试验取得成功, objectType=article, longId=178245, objectId=e1fa1e8245bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1fa1e8245bc, replyNumber=0, likeNumber=55, createdTime=2020-04-22, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1fa1e8245bc, moduleTitle=Onngsertib治疗转移性去势抵抗性前列腺癌的II期临床试验取得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1fa1e8245bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931456, encodeId=8ccc1931456d6, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=Horizon的teprotumumab治疗活动性甲状腺眼病III期临床试验大获成功, objectType=article, longId=161504, objectId=8f841615044d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f841615044d, replyNumber=0, likeNumber=54, createdTime=2019-04-07, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f841615044d, moduleTitle=Horizon的teprotumumab治疗活动性甲状腺眼病III期临床试验大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f841615044d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931471, encodeId=e9a219314e176, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点, objectType=article, longId=174364, objectId=c1da1e436402, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1da1e436402, replyNumber=0, likeNumber=74, createdTime=2019-12-21, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1da1e436402, moduleTitle=阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1da1e436402)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931441, encodeId=972f1931441df, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=艾森新药AC0058美国II期临床试验首例系统性红斑狼疮患者正式入组治疗, objectType=article, longId=154956, objectId=189915495643, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=189915495643, replyNumber=0, likeNumber=62, createdTime=2019-04-24, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=189915495643, moduleTitle=艾森新药AC0058美国II期临床试验首例系统性红斑狼疮患者正式入组治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=189915495643)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931461, encodeId=c2b4193146153, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎，III期临床试验大获成功, objectType=article, longId=164909, objectId=f4ff16490983, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4ff16490983, replyNumber=0, likeNumber=62, createdTime=2020-02-03, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4ff16490983, moduleTitle=礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎，III期临床试验大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4ff16490983)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931446, encodeId=c58b1931446a5, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=JCO：卡铂和紫杉醇对未知原发癌患者的部位特异性治疗：II期临床试验, objectType=article, longId=158471, objectId=e6371584e194, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6371584e194, replyNumber=0, likeNumber=116, createdTime=2019-02-14, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6371584e194, moduleTitle=JCO：卡铂和紫杉醇对未知原发癌患者的部位特异性治疗：II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6371584e194)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1931447, encodeId=5b95193144e6a, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, objectTitle=治疗粘多糖贮积症的基因疗法LYS-SAF302 的II/III期临床试验AAVance正式开始, objectType=article, longId=160342, objectId=a54e16034284, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a54e16034284, replyNumber=0, likeNumber=71, createdTime=2019-12-23, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a54e16034284, moduleTitle=治疗粘多糖贮积症的基因疗法LYS-SAF302 的II/III期临床试验AAVance正式开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a54e16034284)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

II期临床试验

2020-05-29

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

复杂腹腔内感染的治疗：口服和静脉注射Sulopenem的III期临床试验结果

2020-08-07

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

赛诺菲：Dupixent（dupilumab）治疗严重慢性鼻窦炎、鼻息肉的两项III期临床试验取得了积极成果 

2019-09-11

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

葛兰素史克宣布贝利尤单抗治疗狼疮性肾炎患者的III期临床试验取得整体阳性结果

2020-08-26

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

阿斯利康靶向HER2的抗体药物偶联物在II期临床试验中显示出治疗前景

2019-08-16

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

以胸腺素β4为活性成分的新型治疗肽正进行干眼症的III期临床试验

2019-05-20

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

国产艾滋病疫苗II期临床试验启动：1500元补助招志愿者

2020-03-14

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

阿斯利康的EGFR抑制剂Tagrisso在III期临床试验中显著改善NSCLC的总体存活率

2020-06-19

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

赛诺菲/Regeneron的IL-13单抗REGN3500治疗哮喘II期临床试验成功

2020-06-04

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

Sanfilippo综合征A型的基因疗法：基因疗法ABO-102的I/II期临床试验取得阶段性成果

2019-11-17

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

Cymerus MSCs治疗骨关节炎的II期临床试验取得新进展

2020-06-12

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

2019年美国皮肤病学会（AAD）年会：Bermekimab治疗特应性皮炎的II期临床试验取得突破性成果

2020-01-24

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

III期临床试验显示：诺华的CGRP抑制剂Aimovig治疗偏头痛展现出长期疗效

2020-01-31

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

辉瑞公布LYRICA（普瑞巴林）治疗原发性全身强直-阵挛性癫痫发作的III期临床试验结果

2020-03-04

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

Onngsertib治疗转移性去势抵抗性前列腺癌的II期临床试验取得成功

2020-04-22

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

Horizon的teprotumumab治疗活动性甲状腺眼病III期临床试验大获成功

2019-04-07

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

阿斯利康的PD-L1单抗Imfinzi治疗小细胞肺癌III期临床试验达到终点

2019-12-21

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

艾森新药AC0058美国II期临床试验首例系统性红斑狼疮患者正式入组治疗

2019-04-24

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎，III期临床试验大获成功

2020-02-03

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

JCO：卡铂和紫杉醇对未知原发癌患者的部位特异性治疗：II期临床试验

2019-02-14

kksonne (审核中...)

前往app查看评论内容

#II期临床试验#

治疗粘多糖贮积症的基因疗法LYS-SAF302 的II/III期临床试验AAVance正式开始

2019-12-23

科室
- - 订阅+
  - 更多科室
工具
服务